How much revenue does Akeso make?

Akeso reported 3.06 billion CNY in revenue for fiscal year 2025, up 43.9% from 2.12 billion CNY in fiscal year 2024.

Where does Akeso make most of its revenue?

Mainland China: 88% of revenue by region in fiscal year 2025, followed by United States of America (11%).

What companies are similar to Akeso?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Hansoh Pharmaceutical Group Company Limited (3692.HK), Innovent BIO (1801.HK), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), Shanghai Henlius Biotech, Inc. (2696.HK).

Akeso, Inc. (9926.HK) Stock

About Akeso, Inc.

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carc...

At a glance

Akeso reported revenue of 3.06 billion CNY for fiscal year 2025, up 43.9% from fiscal year 2024, and net income of -1.11 billion CNY. Mainland China was its largest region in fiscal year 2025, with 88% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.